Treatment and maintenance may have different aims
A melasma plan can involve reducing visible pigment initially and then limiting recurrence. AAD describes individualized care and the importance of continued sun protection. A short-term medicine is not necessarily the product used for the next stage.[source]
That distinction can be lost in automatic deliveries. A shipment calendar is a commerce feature; a maintenance decision should reflect the clinician’s assessment of response, tolerability and ongoing needs.
A product’s label may rule out indefinite use
TRI-LUMA is expressly not indicated for maintenance treatment. A reader should not assume that a successful initial course authorizes continuing it without review.[source]
Other products have their own instructions and prescribing terms. Cyspera’s retail directions and a custom hydroquinone prescription are not interchangeable plans, even if both are discussed under pigment care.
Agree on the next conversation early
Before starting, ask when follow-up occurs, what signs mean contact sooner and how the routine changes if the skin improves. Keep the full product list available so overlapping actives can be considered.
If discoloration returns, it does not automatically justify a stronger concentration or multiple added treatments. Revisit the diagnosis, triggers and protection with the clinician. A comparison site can explain this decision point and the relevant labels, but it should not provide a universal cycling schedule or promise that recurrence can always be prevented.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- AAD: melasma diagnosis and treatmentAAD guidance rechecked October 10, 2026. · Checked October 10, 2026
- DailyMed: current TRI-LUMA prescribing informationGalderma drug labeling; current accessible version checked October 8, 2026 · Checked October 8, 2026